Publication:
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Placeholder

Organizational Units

Organizational Unit

Program

School / College / Institute

SCHOOL OF MEDICINE

KU Authors

Co-Authors

Dal, Mehmet Sinan
Ulu, Bahar Uncu
Uzay, Ant
Besisik, Sevgi
Yenerel, Mustafa Nuri
Celik, Serhat
Kaynar, Leylagul
Yucel, Orhan Kemal
Deveci, Burak
Sonmez, Mehmet

Publication Date

Language

Embargo Status

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.

Source

Publisher

Springer

Subject

Hematology

Citation

Has Part

Source

Annals of Hematology

Book Series Title

Edition

DOI

10.1007/s00277-022-05052-x

item.page.datauri

Link

Rights

Rights URL (CC Link)

Copyrights Note

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details